Progression-free survival
Figure 5 · Panel A
Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Yeong Hak Bang, Geun-Ho Park, Jin Woo Oh, Soohyun Hwang, Jun-Gi Jeong, Boram Lee, Cheol Yong Joe, Hyemin Kim, Jinyong Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Yoon-La Choi, Chang Ho Ahn, Siraj M Ali, Chan-Young Ock, Se-Hoon Lee
J Immunother Cancer 13(10) e012374
PURPOSE: This study evaluated the dynamic changes in the tumor microenvironment (TME) in patients with non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) using an artificial intelligence (AI)-powered spatial TME analyzer. We then assessed the predictive efficacy of immune-checkpoint inhibitors (ICIs)-based treatment. EXPERIMENTAL DESIGN: An AI-powered whole-slide image analyzer was used to segment cancer areas (CAs) and cancer stroma and to identify tumor-infiltrating lymphocytes (TILs), tertiary lymphoid structures, fibroblasts, and endothelial cells (ECs) in the tumor tissue. We analyzed 143 NSCLC samples after resistance to EGFR-TKIs from two cohorts: (1) 89 patients treated with ICI monotherapy and (2) 54 patients from the ATTLAS phase III trial comparing atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP) versus pemetrexed plus carboplatin. RESULTS: Post-TKI samples showed reduced TILs in the CA (p=0.045) and increased ECs in the CA (p=0.005) compared with pre-TKI samples. These changes differed according to EGFR mutation subtype. Higher TILs in CA were associated with a better overall response rate (ORR) and progression-free survival (PFS). Similarly, higher EC levels in CA correlated with improved ORR and PFS. In the ATTLAS cohort, these factors were associated with clinical benefits from ABCP, with a significant association with TILs and a marginal association with ECs. CONCLUSION: Our findings suggest that EGFR-TKIs affect the immune landscape of patients with EGFR-mutated NSCLC. Higher TILs or ECs in the CA were significantly associated with a favorable response to subsequent ICI-based treatment. TRIAL REGISTRATION NUMBER: NCT03991403.
1 个 Figure · 3 个 KM 面板
Figure 5. Efficacy outcomes with ICI after acquired resistance to EGFR-TKI. ( A ) Progression-free survival with ICIs monotherapy according to the IP after acquired resistance to EGFR-TKI. ( B ) Proportion bar plot indicating best response according to the TILs on CA, and ECs on CA. ( C ) Forest plot of HR (dot) and 95% CI (arrow) for PFS and OS according to the baseline characteristics and variables inferred from AI-powered TME analyzer. ( D–E ) Progression-free survival comparison between the ABCP arm and the PC arm in patients with higher TILs on CA ( D ) or ECs on CA ( E ) following EGFR-TKI treatment in the ATTLAS cohort. ABCP, atezolizumab plus bevacizumab, paclitaxel, and carboplatin; CA, cancer area; CS, cancer stroma; EC, endothelial cell; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; Fibs, fibroblasts; ICI, immune-checkpoint inhibitor; IP, immune-phenotype; PC, pemetrexed plus carboplatin; PD, progressive disease; PD-L1, programmed death-ligand 1; PR, partial response; SD, stable disease; TIL, tumor-infiltrating lymphocyte; TKI, tyrosine kinase inhibitor; TLS, tertiary lymphoid structure; TPS, tumor proportion score.
Figure 5 · Panel A
Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel D
Panel D 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel E
Panel E 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。